###begin article-title 0
###xml 33 38 <span type="species:ncbi:9606">Human</span>
ACC2 Is Expressed at High Levels Human White Adipose and Has an Isoform with a Novel N-Terminus
###end article-title 0
###begin p 1
Conceived and designed the experiments: JC CR KO JK JMJ. Performed the experiments: YH CR PGE KO. Analyzed the data: JC YH CR KO ZK. Contributed reagents/materials/analysis tools: JC CR PGE KO. Wrote the paper: JC CR KO JK JMJ.
###end p 1
###begin p 2
###xml 1007 1014 1007 1014 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">de novo</italic>
###xml 491 496 <span type="species:ncbi:9606">human</span>
###xml 613 618 <span type="species:ncbi:9606">Human</span>
###xml 639 644 <span type="species:ncbi:9606">human</span>
###xml 823 828 <span type="species:ncbi:9606">human</span>
###xml 1178 1183 <span type="species:ncbi:9606">human</span>
Acetyl-CoA carboxylases ACC1 and ACC2 catalyze the carboxylation of acetyl-CoA to malonyl-CoA, regulating fatty-acid synthesis and oxidation, and are potential targets for treatment of metabolic syndrome. Expression of ACC1 in rodent lipogenic tissues and ACC2 in rodent oxidative tissues, coupled with the predicted localization of ACC2 to the mitochondrial membrane, have suggested separate functional roles for ACC1 in lipogenesis and ACC2 in fatty acid oxidation. We find, however, that human adipose tissue, unlike rodent adipose, expresses more ACC2 mRNA relative to the oxidative tissues muscle and heart. Human adipose, along with human liver, expresses more ACC2 than ACC1. Using RT-PCR, real-time PCR, and immunoprecipitation we report a novel isoform of ACC2 (ACC2.v2) that is expressed at significant levels in human adipose. The protein generated by this isoform has enzymatic activity, is endogenously expressed in adipose, and lacks the N-terminal sequence. Both ACC2 isoforms are capable of de novo lipogenesis, suggesting that ACC2, in addition to ACC1, may play a role in lipogenesis. The results demonstrate a significant difference in ACC expression between human and rodents, which may introduce difficulties for the use of rodent models for development of ACC inhibitors.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 404 407 404 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004369-Wakil1">[1]</xref>
###xml 408 411 408 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004369-Barber1">[5]</xref>
Acetyl-CoA carboxylase alpha (ACC1) and beta (ACC2) catalyze the carboxylation of acetyl-CoA to malonyl-CoA. Malonyl-CoA is a substrate for fatty acid synthase and also inhibits carnitine palmitoyltransferase-1, such that malonyl-CoA is a key molecule regulating both the biosynthesis and oxidation of fatty acids. Thus ACC1 and ACC2 are key regulators of the fatty-acid synthesis and oxidation pathways [1]-[5].
###end p 4
###begin p 5
###xml 204 213 204 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004369.s001">Figure S1</xref>
###xml 393 396 393 396 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 426 429 426 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004369-AbuElheiga1">[6]</xref>
###xml 431 434 431 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004369-Harada1">[7]</xref>
###xml 447 450 447 450 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 581 584 581 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004369-AbuElheiga2">[8]</xref>
###xml 585 589 585 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004369-AbuElheiga3">[10]</xref>
###xml 691 694 691 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004369-Harada1">[7]</xref>
###xml 696 700 696 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004369-Harwood1">[11]</xref>
###xml 701 705 701 705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004369-Shi1">[13]</xref>
###xml 797 804 797 804 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">de novo</italic>
###xml 920 924 920 924 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004369-Bianchi1">[14]</xref>
###xml 926 930 926 930 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004369-Ha1">[15]</xref>
###xml 1077 1081 1077 1081 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004369-Bianchi1">[14]</xref>
###xml 1082 1086 1082 1086 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004369-Zhang1">[19]</xref>
###xml 1234 1238 1234 1238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004369-Hardie1">[20]</xref>
###xml 1239 1243 1239 1243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004369-Ruderman1">[22]</xref>
###xml 1424 1428 1412 1416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004369-AbuElheiga4">[18]</xref>
###xml 1642 1646 1618 1622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004369-Ha1">[15]</xref>
###xml 383 388 <span type="species:ncbi:10090">mouse</span>
###xml 451 455 <span type="species:ncbi:10090">mice</span>
###xml 888 891 <span type="species:ncbi:10116">rat</span>
###xml 896 901 <span type="species:ncbi:10090">mouse</span>
In mammals, both of ACC1 and ACC2 are multifunctional enzymes, containing biotin carboxyl carrier, biotin carboxylase, and carboxyl transferase domains all within a single polypeptide chain (Supplemental Figure S1). Although ACC1 and ACC2 share over 70% protein sequence identity and have the same enzymatic activity, they are believed to have distinct cellular roles. Indeed, while mouse ACC1-/- mutants are embryonic lethal [6], [7], mutant ACC2-/- mice have a normal lifespan but higher fat oxidation rate in muscle and adipose tissues and are resistant to diet-induced obesity [8]-[10], observations which have made ACC2 an attractive target for treatment of obesity and type 2 diabetes [7], [11]-[13]. ACC1 is cytosolic and believed to be the primary acetyl-CoA carboxylase (ACC) involved in de novo fatty-acid synthesis. This is supported by observations of high ACC1 expression in rat and mouse lipogenic tissues [14], [15]. In contrast, ACC2 has been reported to regulate fatty-acid oxidation through malonyl-CoA mediated inhibition of carnitine palmitoyltransferase-1 [14]-[19]. Physiological studies have also linked ACC2 expression in muscle to physical exercise, corroborating a link between ACC2 and fatty-acid oxidation [20]-[22]. Immunofluorescence microscopy studies suggest that ACC2 is preferentially localized to the mitochondria, possibly due to the unique approximately220 amino acid N-terminus of ACC2 [18]. This N-terminus includes a leader sequence of approximately20 hydrophobic residues that has been hypothesized to be responsible for mitochondrial localization and thus the functional difference between two genes [15].
###end p 5
###begin p 6
###xml 275 279 275 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004369-Bianchi1">[14]</xref>
###xml 281 285 281 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004369-Winz1">[23]</xref>
###xml 376 380 376 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004369-Ha1">[15]</xref>
###xml 608 611 608 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004369-Barber1">[5]</xref>
###xml 143 146 <span type="species:ncbi:10116">rat</span>
###xml 296 301 <span type="species:ncbi:9606">human</span>
###xml 478 483 <span type="species:ncbi:9606">human</span>
Arguments against a lipogenic role for ACC2 are based primarily on preferential expression of ACC2 in rodents within non-lipogenic tissues. In rat, for example, ACC2 is expressed in muscle, heart, liver, mammary gland, and brown adipose but was not observed in white adipose [14], [23]. In prior human expression studies, ACC2 transcript levels were measured in eight tissues [15], and the highest expression of ACC2 was observed in skeletal muscle. However, ACC2 expression in human adipose tissue was not assayed. In addition, EST sequence databases suggest the existence of novel alternative splice forms [5].
###end p 6
###begin p 7
###xml 488 495 488 495 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">de novo</italic>
###xml 50 55 <span type="species:ncbi:9606">human</span>
###xml 132 137 <span type="species:ncbi:9606">human</span>
###xml 231 236 <span type="species:ncbi:9606">human</span>
###xml 259 264 <span type="species:ncbi:9606">human</span>
###xml 317 322 <span type="species:ncbi:9606">human</span>
###xml 455 460 <span type="species:ncbi:9606">human</span>
###xml 797 803 <span type="species:ncbi:9606">humans</span>
Since ACC inhibition is a candidate treatment for human metabolic syndrome, there is a clear need to characterize ACC expression in human tissues. Here we present RNA and protein evidence that ACC2 is expressed at higher levels in human white adipose than in human skeletal muscle, and that the expression of ACC2 in human white adipose is higher than that of ACC1. Further, we show RNA and protein evidence for a second ACC2 isoform that is expressed in human adipose, has enzymatic and de novo lipogenic activity, is endogenously expressed, and has a distinct N-terminus lacking the proposed N-terminal mitochondrial localization sequence. These observations suggest ACC2 may play a role in fatty-acid synthesis, and that there may be molecular differences in fat metabolism between rodents and humans.
###end p 7
###begin title 8
Results
###end title 8
###begin title 9
###xml 41 46 <span type="species:ncbi:9606">human</span>
ACC2 mRNA is present at higher levels in human adipose tissue than ACC1
###end title 9
###begin p 10
###xml 135 139 135 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004369-Castle1">[24]</xref>
###xml 186 194 186 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004369-g001">Figure 1</xref>
###xml 361 382 361 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 38 43 <span type="species:ncbi:9606">human</span>
Expression levels of ACC1 and ACC2 in human tissues, each pooled from multiple donors, were examined using oligonucleotide microarrays [24] and calibrated quantitative real-time RT-PCR (Figure 1). Microarray data were derived from custom microarray patterns, with probes placed in every exon and exon-exon junction, and a random-priming amplification protocol (Materials and Methods). Intensities for ACC1 and ACC2 are the average of over 100 probes per gene. In the tissues examined, ACC1 is expressed at higher levels than ACC2 in brain, prostate, and ovary, whereas ACC2 is expressed at higher levels in adipose, mammary gland, muscle, heart, gastrointestinal tissues, liver, kidney, thyroid, pituitary, and adrenal gland.
###end p 10
###begin title 11
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human ACC1 and ACC2 mRNA expression from microarray and TaqMan (inset) measurements.
###end title 11
###begin p 12
Microarray data show the average probe intensity from 113 (ACC1) and 120 (ACC2) probes and are ordered based on ACC1 expression. Calibrated TaqMan data were scaled to a maximum of 100.
###end p 12
###begin p 13
###xml 378 393 378 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004369-g001">Figure 1, inset</xref>
We validated these results using calibrated real-time RT-PCR (Taqman). Calibrated Taqman involves construction of a standard curve derived from dilution series measurements, resulting in highly quantitative measurements permitting cross-gene and cross-tissue comparisons. We find the relative expression of ACC1 and ACC2 transcripts measured by microarray and quantitative PCR (Figure 1, inset) are in good agreement. Both datasets clearly show that ACC2 is strongly expressed in adipose tissue, at levels greater than in muscle.
###end p 13
###begin title 14
A transcript variant of ACC2 with a novel N-terminus
###end title 14
###begin p 15
###xml 250 259 250 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004369-g002">Figure 2A</xref>
###xml 442 451 442 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004369-g002">Figure 2A</xref>
###xml 453 462 453 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004369.s002">Figure S2</xref>
###xml 708 717 708 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004369-g002">Figure 2B</xref>
###xml 19 24 <span type="species:ncbi:9606">human</span>
###xml 39 44 <span type="species:ncbi:9606">human</span>
###xml 49 54 <span type="species:ncbi:10090">mouse</span>
###xml 61 66 <span type="species:ncbi:9606">human</span>
###xml 80 85 <span type="species:ncbi:10090">mouse</span>
###xml 354 359 <span type="species:ncbi:9606">human</span>
###xml 372 379 <span type="species:ncbi:9031">chicken</span>
When mapped to the human genome, three human and mouse ESTs, human CA392208 and mouse BB854145 and BB866065, suggest the existence of an additional transcribed region between the first and second exons of the RefSeq ACC2 isoform (ACC2.v1) NM_001093 (Figure 2A). Other genomic data support this interpretation, including a candidate ATG start codon, high human, rodent and chicken sequence conservation, and the absence of termination codons (Figure 2A, Figure S2). Usage of this ATG codon as start site could generate an in-frame ACC2 protein in which the first 218 amino acids of the known RefSeq protein NP_001084, including the hydrophobic N-terminus, were replaced with a novel 16 amino-acid N-terminus (Figure 2B). This variant, referred to in what follows as ACC2.v2, is less likely to encode a membrane-associated protein because it lacks the putative mitochondrial localization sequence.
###end p 15
###begin title 16
Novel ACC2 isoform.
###end title 16
###begin p 17
###xml 139 143 139 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004369-Davuluri1">[33]</xref>
###xml 271 275 271 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004369-Siepel1">[34]</xref>
###xml 68 73 <span type="species:ncbi:9606">human</span>
###xml 240 245 <span type="species:ncbi:9606">human</span>
###xml 247 252 <span type="species:ncbi:10090">mouse</span>
###xml 254 257 <span type="species:ncbi:10116">rat</span>
###xml 263 270 <span type="species:ncbi:9031">chicken</span>
###xml 741 746 <span type="species:ncbi:10090">mouse</span>
(A) Genomic alignment of the 5' end of RefSeq transcript NM_001093, human EST CA392208 (exons are shown as boxes), 'FirstExon' predictions [33], including the CpG island, promoter region, and first exon location, and conservation score for human, mouse, rat, and chicken [34]. The green and red boxes in the top two rows are the alternative first exons. The vertical, dashed blue line in the zoomed image (lower left panel) shows the predicted start ATG codon. The gel image using RT-PCR primers in novel exon 1 and known exon 5 shows intensity in all tissues tested at the predicted size. (B) The RNA sequence of the novel exon 1 (red), the start of exon 2 (black), and the predicted protein. The first base is the beginning of the aligned mouse EST BB866065. The RT-PCR primer target sequence is underlined.
###end p 17
###begin title 18
The novel ACC2.v2 transcript is expressed in white adipose
###end title 18
###begin p 19
###xml 202 211 202 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004369-g002">Figure 2A</xref>
###xml 396 401 <span type="species:ncbi:9606">human</span>
To validate transcription of this computational prediction, we designed RT-PCR primers from the novel exon 1 to the known exon 5. The result shows clear expression of the novel band in several tissues (Figure 2A). Cloning followed by sequencing of this band confirmed the sequence identity, which has been deposited in dbEST as EH093926. This sequence cannot be mapped to any other region of the human genome, including the ACC1 locus, and thus experimentally confirms ACC2.v2 transcription.
###end p 19
###begin title 20
###xml 40 45 <span type="species:ncbi:9606">human</span>
###xml 47 50 <span type="species:ncbi:10116">rat</span>
###xml 56 61 <span type="species:ncbi:10090">mouse</span>
Expression of ACC1 and ACC2 isoforms in human, rat, and mouse tissues
###end title 20
###begin p 21
###xml 148 162 148 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004369-g003">Figure 3 (top)</xref>
###xml 578 605 578 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004369-g003">Figures 3, middle and lower</xref>
###xml 87 92 <span type="species:ncbi:9606">human</span>
###xml 168 173 <span type="species:ncbi:9606">human</span>
###xml 555 560 <span type="species:ncbi:10090">mouse</span>
###xml 565 568 <span type="species:ncbi:10116">rat</span>
###xml 699 704 <span type="species:ncbi:9606">human</span>
###xml 778 783 <span type="species:ncbi:9606">human</span>
###xml 798 801 <span type="species:ncbi:10116">rat</span>
###xml 806 811 <span type="species:ncbi:10090">mouse</span>
###xml 1049 1055 <span type="species:ncbi:9606">humans</span>
###xml 1145 1150 <span type="species:ncbi:9606">human</span>
The relative abundances of ACC1, ACC2.v1 and ACC2.v2 transcripts were measured in five human tissues using calibrated real-time RT-PCR. As shown in Figure 3 (top), the human ACC2.v2 transcript is less abundant than the known isoform but is significantly expressed in all five tissues tested. The highest absolute expression level of ACC2.v2 is observed in adipose tissue, where the splice variant accounts for over 20% of ACC2 expression, at levels comparable to ACC1 expression. We also measured the levels of ACC1, ACC2.v1, and ACC2.v2 in corresponding mouse and rat tissues (Figures 3, middle and lower). The ratio of ACC1 and ACC2 expression is dramatically different between rodent tissues and human tissues, particularly in the lipogenic tissues adipose and liver. Unlike human tissues, both rat and mouse adipose express ACC2 at low levels, significantly lower than ACC1, and rodent liver contains more ACC1 than ACC2. Furthermore, rodent muscle expresses ACC2 at levels much higher than seen in rodent adipose, different from the pattern in humans. Finally, the ratio of ACC2.v1 to ACC2.v2 transcript expression is similar in rodent and human tissues, further suggesting that the novel ACC2.v2 product is regulated and may be functional.
###end p 21
###begin title 22
###xml 45 50 <span type="species:ncbi:9606">human</span>
###xml 52 57 <span type="species:ncbi:10090">mouse</span>
###xml 63 66 <span type="species:ncbi:10116">rat</span>
Expression of ACC1 and ACC2 mRNA isoforms in human, mouse, and rat tissues.
###end title 22
###begin p 23
###xml 115 122 115 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Methods</xref>
TaqMan probes were designed to specifically monitor each transcript and were calibrated using standard curves (see Methods). Expression levels were scaled for each species such that the maximum ACC1 or total ACC2 expression (ACC2.v1 plus ACC2.v2) is 100.
###end p 23
###begin title 24
###xml 36 41 <span type="species:ncbi:9606">human</span>
###xml 43 46 <span type="species:ncbi:10116">rat</span>
###xml 52 57 <span type="species:ncbi:10090">mouse</span>
ACC1 and ACC2 protein expression in human, rat, and mouse tissue
###end title 24
###begin p 25
###xml 233 241 233 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004369-g004">Figure 4</xref>
###xml 956 965 956 965 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004369.s003">Figure S3</xref>
###xml 463 468 <span type="species:ncbi:9606">human</span>
###xml 509 514 <span type="species:ncbi:9606">human</span>
###xml 587 592 <span type="species:ncbi:9606">Human</span>
###xml 594 597 <span type="species:ncbi:10116">rat</span>
###xml 603 608 <span type="species:ncbi:10090">mouse</span>
###xml 646 649 <span type="species:ncbi:10116">Rat</span>
###xml 654 659 <span type="species:ncbi:10090">mouse</span>
###xml 848 853 <span type="species:ncbi:9606">human</span>
To determine if these transcript expression patterns reflected enzyme levels, we assayed ACC1 and ACC2 protein levels by Western blot using streptavidin and antibodies specific to the middle of ACC1 and to the N terminus of ACC2.v1 (Figure 4). A single biotin molecule covalently couples to a single ACC molecule, permitting qualitative determination of ACC1 and ACC2 protein expression with streptavidin-HRP (anti-biotin). A bright ACC2 band was observed in the human muscle sample (first column). The three human adipose samples probed all show ACC2 bands and less intense ACC1 bands. Human, rat, and mouse liver showed a mix of ACC1 and ACC2. Rat and mouse white adipose show intensities at the ACC1 band and lower intensities at the ACC2 band. These results, while highly qualitative, suggest that the ACC2 protein is endogenously expressed in human adipose. We also find evidence suggesting the ACC2.v2 protein is endogenously expressed (Supplemental Figure S3).
###end p 25
###begin title 26
ACC protein expression, measured with three different antibodies: ACC1+ACC2 (top row), ACC1-specific (middle row), and ACC2.v1-specific (bottom row).
###end title 26
###begin p 27
###xml 5 10 <span type="species:ncbi:9606">human</span>
Each human adipose and liver sample is from a different individual. Streptavidin targets an endogenous biotin molecule within each ACC isoforms, so its intensity reflects molar ratio of each ACC isoform. The ACC2.v1 antibody specifically targets the ACC2.v1 N-terminus and does not detect ACC2.v2 protein.
###end p 27
###begin title 28
ACC2.v2, ACC2.v1, and ACC1 protein activity
###end title 28
###begin p 29
###xml 341 350 317 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004369-g005">Figure 5A</xref>
###xml 408 416 384 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 416 418 392 394 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
###xml 420 421 396 397 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 579 588 555 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004369-g005">Figure 5B</xref>
###xml 661 662 637 638 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sub>
###xml 688 689 664 665 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 737 738 713 714 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sub>
###xml 836 837 804 805 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 862 869 830 837 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0004369-t001">Table 1</xref>
###xml 934 935 902 903 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sub>
###xml 984 985 952 953 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 1007 1014 975 982 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">de novo</italic>
###xml 1101 1103 1069 1071 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
###xml 1148 1157 1116 1125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004369-g005">Figure 5C</xref>
###xml 618 623 <span type="species:ncbi:9606">human</span>
To confirm the ACC2.v2 transcript isoform generates protein, we cloned ACC2.v2 and ACC2.v1 and overexpressed them in FM3A cells, a mammary carcinoma-derived cell line. Recombinant ACC2.v2 and ACC2.v1 were detected at expected molecular weights of approximately255 and approximately277 kDa, respectively and biotinylated in Western blotting (Figure 5A). We investigated ACC enzymological properties using the in vitro14CO2 fixation assay using lysate from FM3A cells. Overexpression of either ACC2.v2 or ACC2.v1 increases ACC enzymatic activity >20-fold relative to vector alone (Figure 5B). Using purified recombinant human ACC1, ACC2.v1 and ACC2.v2, we found Km values for acetyl-CoA, CO2 and ATP among ACC subtypes and variants, with Km values for acetyl-CoA between 51 and 110 microM; for ATP between 44 and 110 microM; and for NaHCO3 between 2.9 and 6.5 mM (Table 1). Relative to ACC2.v1, ACC2.v2 showed 2 to 3-fold increases in Km values for ACC2.v2 with respect to ATP and NaHCO3. Finally, we assayed de novo lipogenesis (DNL) activity in FM3A cells overexpressing recombinant ACC clones using [14C]acetate incorporation as a marker for DNL (Figure 5C). After overexpression, incorporation was first measured in the presence of a non-specific ACC inhibitor, labeled 'compound A,' as a control, and then without inhibitor. Overexpression of ACC1 increased cellular DNL activity almost 4-fold relative to vector alone. Cells expressing either ACC2.v2 or ACC2.v1 showed an approximately 2-fold relative increase in DNL.
###end p 29
###begin title 30
Expression and activities of ACC2 proteins.
###end title 30
###begin p 31
###xml 390 398 390 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 398 400 398 400 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
###xml 402 403 402 403 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 452 454 452 454 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
###xml 474 476 474 476 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
###xml 621 623 621 623 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
###xml 724 726 724 726 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
(A) Expression of recombinant ACC2.v1 and ACC2.v2 proteins in FM3A cells. Recombinant ACC proteins in cell lysates from FM3A cells overexpressing ACC isoforms were detected by Western blotting. Arrows mark the locations of ACC2.V1, ACC1, and ACC2.v2, from top to bottom. (B) ACC activities of recombinant ACC2.v1 and ACC2.v2 protein. ACC activities in FM3A cell lysates were measured by an in vitro14CO2 fixation assay, measuring the incorporation of [14C]bicarbonate into [14C]malonyl-CoA. (C) DNL activity in FM3A cells overexpressing recombinant ACCs. DNL activities were measured as incorporated radio activities of [14C]acetate into cells in the presence of Simvastatin, a HMG-CoA reductase inhibitor. The non-specific[14C]acetate incorporation was determined in the presence of 10 microM a specific dual ACC1 and ACC2 inhibitor, labeled 'compound A,' and subtracted from total DNL activity in each FM3A clone.
###end p 31
###begin title 32
###xml 1 2 1 2 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sub>
Km values.
###end title 32
###begin title 33
Discussion
###end title 33
###begin p 34
###xml 96 100 96 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004369-Bianchi1">[14]</xref>
###xml 102 106 102 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004369-Winz1">[23]</xref>
###xml 289 293 289 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004369-Bianchi1">[14]</xref>
###xml 474 482 474 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004369-g001">Figure 1</xref>
###xml 708 712 708 712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004369-Widmer1">[25]</xref>
###xml 323 328 <span type="species:ncbi:10090">mouse</span>
###xml 380 385 <span type="species:ncbi:10090">mouse</span>
###xml 418 423 <span type="species:ncbi:9606">Human</span>
###xml 485 490 <span type="species:ncbi:9606">Human</span>
###xml 585 590 <span type="species:ncbi:9606">human</span>
###xml 608 613 <span type="species:ncbi:9606">Human</span>
###xml 687 692 <span type="species:ncbi:9606">human</span>
###xml 852 857 <span type="species:ncbi:9606">human</span>
###xml 951 954 <span type="species:ncbi:9615">dog</span>
###xml 962 975 <span type="species:ncbi:9544">rhesus monkey</span>
###xml 1029 1032 <span type="species:ncbi:9615">dog</span>
Our measurements of ACC1 and ACC2 transcript levels in rodent samples agree with published data [14], [23] showing high levels of ACC1 in adipose, high levels of ACC2 in heart and skeletal muscle tissues, and higher levels of ACC1 than ACC2 in liver. Also in agreement with published data [14], our microarray profiling of mouse brown adipose shows higher ACC2 expression than in mouse white adipose (data not shown). Human tissues show a very different expression pattern (Figure 1). Human adipose expresses ACC2 at levels four times higher than ACC1, a higher level than observed in human skeletal muscle. Human liver expresses more ACC2 than ACC1. Although ACC2 was first cloned from human adipose tissue [25], attention has focused on the role of ACC2 in fatty-acid oxidation in muscle tissue, and, to our knowledge, the high expression of ACC2 in human adipose has not previously been reported. Furthermore, microarray expression profiling in 53 dog and 65 rhesus monkey tissues (data not shown) show highest ACC2 levels in dog and rhesus adipose. Thus, ACC2 expression in primate and canine adipose is different than in rodent adipose, and may represent a species difference in fatty-acid regulation.
###end p 34
###begin p 35
###xml 118 123 <span type="species:ncbi:9606">human</span>
Although we have shown there are significant differences in ACC2 transcript and protein expression between rodent and human tissues, we cannot rule out the possibility that a part of the observed differences is due to variation in tissue dissection, RNA isolation, or sample pooling. However, adipose is a relatively homogeneous tissue, such that different dissection methods would not be expected to produce large changes in the cell-type composition of the isolated adipose tissue. Secondly, adipose samples collected from multiple vendors, for both individuals and pools of individuals, consistently show similar mRNA expression profiles that cluster together in a background of hundreds of other tissue samples (data not shown), suggesting that dissection and RNA isolation differences tend to produce relatively small effects on mRNA profiles.
###end p 35
###begin p 36
###xml 294 303 258 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004369-g005">Figure 5A</xref>
###xml 318 328 282 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004369.s001">Figures S1</xref>
###xml 330 332 294 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004369.s003">S3</xref>
###xml 779 787 743 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004369-g003">Figure 3</xref>
###xml 84 89 <span type="species:ncbi:9606">human</span>
###xml 701 706 <span type="species:ncbi:10090">mouse</span>
###xml 711 714 <span type="species:ncbi:10116">rat</span>
We demonstrate the existence of a novel ACC2 isoform (ACC2.v2) that is expressed in human white adipose tissue and has enzymatic and DNL activity. The protein is smaller (approximately255 kDa) than that of ACC1 (approximately265 kDa) and the known ACC2 protein (ACC2.v1, approximately277 kDa) (Figure 5A, Supplemental Figures S1, S3). This form lacks the hydrophobic N-terminus found in the known ACC2 isoform, including the putative mitochondrial localization sequence but has all three catalytic domains essential for ACC enzyme activity. The ACC2.v2 mRNA accounts for the majority of ACC2 transcripts in testis, over 20% in adipose and approximately 5% in skeletal muscle. ACC2.v2 is also found in mouse and rat and is expressed at ratios similar to ACC2.v1 in these species (Figure 3), suggesting that the novel isoform is similarly regulated between species.
###end p 36
###begin p 37
###xml 489 490 489 490 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sub>
###xml 541 545 541 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004369-Saddik1">[16]</xref>
###xml 969 973 969 973 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004369-Winz1">[23]</xref>
###xml 975 979 975 979 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004369-Thampy1">[26]</xref>
###xml 980 984 980 984 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004369-Chen1">[28]</xref>
###xml 1288 1291 1288 1291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004369-Harada1">[7]</xref>
###xml 1338 1344 1338 1344 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 1344 1347 1344 1347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004369-Oh1">[9]</xref>
###xml 1357 1360 1357 1360 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 3 8 <span type="species:ncbi:9606">human</span>
###xml 1151 1156 <span type="species:ncbi:9606">human</span>
###xml 1264 1268 <span type="species:ncbi:10090">mice</span>
###xml 1361 1365 <span type="species:ncbi:10090">mice</span>
###xml 1565 1571 <span type="species:ncbi:9606">humans</span>
In human adipose, over 20% of the highly expressed ACC2 mRNA is in the form of ACC2.v2, which is expressed at levels comparable to ACC1. ACC2.v2 and ACC1 transcripts encode proteins that are 76% identical (87% similar), and the biotin carboxylation and carboxyl transferase regions are 84% and 81% identical (93% and 91% similar), respectively. The lack of the first coding exon of ACC2.v1 makes the ACC2.v2 protein sequence more similar to ACC1. Previous enzyme kinetics show only lower Km for ACC1 than for ACC2 for acetyl-CoA and citrate [16], and our data suggest ACC2.v1 and ACC2.v2 have comparable ACC activity. All recombinant ACC isoforms tested, ACC1, ACC2.v1, and ACC2.v2, showed DNL activity in cells. However, given the moderate DNL activity of ACC2.v2 despite its level of protein expression, ACC2.v2 may not be as efficiently coupled to DNL pathway as ACC1. While cellular activity is also dependent on mRNA translational rates and phosphorylation states [23], [26]-[28], these expression and enzymatic and DNL activity results suggest that ACC2 isoforms, both ACC2.v1 and ACC2.v2, are capable of contributing to fatty-acid synthesis in human adipose tissue. This hypothesis would also help explain the observation that liver-specific ACC1 deficient mice showed hepatic DNL [7], and is consistent with the observation by Oh et al.[9] that ACC2-/- mice showed not only increased fatty-acid oxidation but also decreased fat levels in adipose. Finally, our results also suggest ACC2 specific inhibition could result in different physiological effects in humans than in rodents.
###end p 37
###begin title 38
Materials and Methods
###end title 38
###begin title 39
Microarray data
###end title 39
###begin p 40
###xml 209 213 209 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004369-Johnson1">[29]</xref>
###xml 415 419 415 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004369-Castle1">[24]</xref>
###xml 428 429 428 429 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 555 559 555 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004369-Castle1">[24]</xref>
###xml 655 659 655 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004369-Hughes1">[30]</xref>
###xml 254 259 <span type="species:ncbi:9606">human</span>
###xml 284 289 <span type="species:ncbi:9606">human</span>
Custom oligonucleotide microarrays were purchased from Agilent Technologies (Palo Alto, California). We designed these arrays to monitor the expression of 18,000 genes and associated alternate splicing events [29]. After alignment of 107,551 full-length human mRNA transcripts to the human genome, probes were designed to target every exon (60 mers) and every exon-exon junction (36 mers on 10 nucleotide T stilts) [24]. Poly[A]+ mRNA was amplified with a full-length amplification method using random-priming sequences to reproduce the entire transcript [24]. Fluorescent dye-labeling, hybridization conditions, and scanning were performed as previously [30]. Each amplified sample was hybridized twice against a common reference pool in a dye-swap experiment. Intensities shown are the mean of all probes for each transcript (113 for ACC1 and 120 for ACC2), after normalization using a common reference pool. Error bars estimate measurement error and not biological variation.
###end p 40
###begin title 41
Tissue samples
###end title 41
###begin p 42
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 177 182 <span type="species:ncbi:9606">Human</span>
###xml 257 262 <span type="species:ncbi:10090">Mouse</span>
###xml 267 270 <span type="species:ncbi:10116">rat</span>
###xml 344 349 <span type="species:ncbi:9606">Human</span>
###xml 479 498 <span type="species:ncbi:10116">Sprague-Dawley rats</span>
###xml 550 554 <span type="species:ncbi:10090">mice</span>
Human tissues and cell line samples were purchased as mRNA or total RNA (Clontech, Mountain View, California). Each tissue sample was pooled from multiple donors, typically 12. Human adipose tissue consisted of subcutaneous epithelial white adipose tissue. Mouse and rat tissues were purchased from Biochain (Hayward, California) and Clontech. Human protein samples were purchased from Biochain and Biopredic International (Rennes, France) as tissue lysate or frozen block, Male Sprague-Dawley rats from Japan SLC, (Hamamatsu, Japan) and C57Black/6J mice from CLEA Japan (Tokyo, Japan).
###end p 42
###begin title 43
Genomic analyses
###end title 43
###begin p 44
###xml 78 82 78 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004369-Florea1">[31]</xref>
###xml 113 117 113 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004369-Mott1">[32]</xref>
###xml 156 160 156 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004369-Davuluri1">[33]</xref>
###xml 209 213 209 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004369-Siepel1">[34]</xref>
###xml 258 262 258 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004369-Karolchik1">[35]</xref>
###xml 18 23 <span type="species:ncbi:9606">human</span>
###xml 87 92 <span type="species:ncbi:9606">human</span>
###xml 122 127 <span type="species:ncbi:10090">mouse</span>
###xml 165 170 <span type="species:ncbi:9606">human</span>
###xml 171 176 <span type="species:ncbi:10090">mouse</span>
###xml 177 180 <span type="species:ncbi:10116">rat</span>
###xml 181 188 <span type="species:ncbi:9031">chicken</span>
Alignments to the human genome (NCBI Build 34, USCS hg16) were done with sim4 [31] for human ESTs and EST_GENOME [32] for mouse ESTs. FirstExon predictions [33] and human/mouse/rat/chicken conservation scores [34] were downloaded from UCSC genomic databases [35].
###end p 44
###begin title 45
RT-PCR
###end title 45
###begin p 46
###xml 13 21 13 21 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004369.s004">Table S1</xref>
###xml 256 260 256 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004369-Johnson1">[29]</xref>
Supplemental Table S1 lists the RT-PCR primer sequences to monitor the known and novel first exons of ACC2. Reverse transcription-polymerase chain reaction (RT-PCR) amplification from tissue-specific mRNA or total RNA was performed as previously described [29]. The oligonucleotides were obtained from Qiagen (Valencia, California). Amplicons were subcloned into pCR2.1 using a TOPO-TA cloning kit (Invitrogen Corp., Carlsbad, California). Sequencing was performed by a commercial vendor (Lark Technologies Inc., Houston, Texas).
###end p 46
###begin title 47
Quantitative PCR
###end title 47
###begin p 48
###xml 152 160 152 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004369.s004">Table S1</xref>
###xml 762 766 758 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004369-Essentials1">[36]</xref>
###xml 102 107 <span type="species:ncbi:9606">human</span>
###xml 112 117 <span type="species:ncbi:10090">mouse</span>
TaqMan primer and probe sequences used to monitor ACC1, ACC2.v1, and ACC2.v2 levels quantitatively in human and mouse tissues are shown in Supplemental Table S1. ACC2.v1 is the isoform defined by transcript NM_001093 and ACC2.v2 is the novel isoform defined here. TaqMan primer-probe reagents were obtained through the Applied Biosystems Assays-by-Design custom assay service (Foster City, CA). Probe sequences were designed to straddle a unique splice junction characteristic of each alternative splice form. TaqMan assays were performed on an ABI 7900 real time PCR instrument in 10 microl assays that were run in triplicate in a 384-well format optical PCR plate. The assays were calibrated with isoform-specific RT-PCR clones using the standard curve method [36]. Standard curves generated from plasmid clones were linear across at least six orders of magnitude, and all reported values derived for total tissue RNA fell within the range of these standard curves. RNA was converted to cDNA for TaqMan measurements using a commercially available kit from Applied Biosystems. All assays were normalized on a tissue-to-tissue basis by adding a constant amount of input total RNA into the RT reaction.
###end p 48
###begin title 49
Western blotting
###end title 49
###begin p 50
###xml 641 649 641 649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004369.s005">Table S2</xref>
###xml 960 968 960 968 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004369.s005">Table S2</xref>
###xml 1107 1115 1107 1115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004369.s005">Table S2</xref>
###xml 991 998 <span type="species:ncbi:9986">rabbits</span>
Total protein samples were separated using 3-8% Tris-Acetate polyacrylamide gel electrophoresis (Invitrogen), and then transferred to PVDF membrane (Immobilon-P, Millipore, Billerica, Massachusetts). Membranes were blocked with Block Ace reagent (Dainippon Sumitomo Pharma Co., Ltd, Osaka, Japan/Snow Brand Milk Product Co. Ltd, Tokyo, Japan), and then incubated with HRP-conjugated streptavidin (Zymed Laboratories, South San Francisco, CA) or corresponding polyclonal antibodies followed by HRP-conjugated 2nd antibody according to the manufacturers (Pierce Biotechnology, Inc., Rockford, IL). Antibody dilutions are shown in Supplemental Table S2. Chemiluminescent detection was performed using SuperSignal West Femto Maximum Sensitivity Substrate (Pierce) and LAS-3000 luminescent image analyzer (FUJIFILM Corp., Tokyo, Japan). Polyclonal antibodies specific for ACC1, ACC2.v1 and ACC2.v2 were prepared by immunizing of polypeptides, shown in Supplemental Table S2, to New Zealand white rabbits. The anti-ACC2.v1 antibody was raised with N-terminal peptide for ACC2.v1 but not for ACC2.v2 (Supplemental Table S2).
###end p 50
###begin title 51
Cloning and expression
###end title 51
###begin p 52
###xml 181 226 181 226 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GCCTAGGTAATGGTCTTGCTTCTTTGTCTATCTTGTCTG-3&#8242;</named-content>
###xml 237 271 237 271 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-ACCGGTGGTGGAGGCCGGGCTGTCCATG-3&#8242;</named-content>
###xml 776 859 776 859 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GCCTAGGTAATGAGTCCTGCCAAGTGCAAGATCTGTTTCCCTGATCGCGAAGTAAAGCCGAGCATGTCGGGACTCCA-3&#8242;</named-content>
###xml 870 894 870 894 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GGCCGGTGCTTCCTCAAC 3&#8242;</named-content>
###xml 1497 1498 1491 1492 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 16 21 <span type="species:ncbi:9606">human</span>
###xml 61 66 <span type="species:ncbi:9606">human</span>
###xml 1127 1132 <span type="species:ncbi:10090">mouse</span>
###xml 1411 1417 <span type="species:ncbi:9913">bovine</span>
The full-length human ACC2.v1 cDNA was amplified by PCR from human skeletal muscle Marathon-Ready cDNA (Clontech) was used as the template using the following primer pair: forward, 5'-GCCTAGGTAATGGTCTTGCTTCTTTGTCTATCTTGTCTG-3'; reverse, 5'-ACCGGTGGTGGAGGCCGGGCTGTCCATG-3'. The amplified product was cloned into a pcDNA5/FRT/V5-His-TOPO vector (Invitrogen) with an added V5 epitope and His tags at the C-terminus, and was confirmed by sequencing. The plasmid was then digested with AvrII and PmeI, and the cDNA fragment was subcloned into the SpeI/EcoRV site of pEFcDNA3 (Invitrogen) vector. The ACC2.v2 cDNA was prepared by replacement of the ACC2.v1 specific N-terminus with that of ACC2.v2 by PCR using the ACC2.v1 cDNA as a template and the following primer pair: forward, 5'-GCCTAGGTAATGAGTCCTGCCAAGTGCAAGATCTGTTTCCCTGATCGCGAAGTAAAGCCGAGCATGTCGGGACTCCA-3', reverse, 5'-GGCCGGTGCTTCCTCAAC 3'. The PCR product was then digested with AvrII/HindIII and exchanged with that of ACC2.v1 cDNA to construct a full-length ACC2.v2 cDNA clone. The ACC2.v1 and ACC2.v2 expression plasmids and pEFcDNA3 vector were introduced into FM3A (mouse mammary carcinoma) cells (RIKEN cell bank, #RCB0086) using Lipofectaimine 2000 (Invitrogen) or Effectene Transfection Reagent (Qiagen, Hilden, Germany), according to manufacturers' instructions. The FM3A cells were cultured in RPMI 1640 medium (Invitrogen) containing 10% fetal bovine serum (HyClone, Logan, UT) and 1 mg/ml G418 (Invitrogen) at 37degreesC in 5% CO2, 95% air to obtain stable transfectants. Cell lysate was prepared and subjected to ACC enzyme assay and Western blot analysis.
###end p 52
###begin title 53
Immunoprecipitation
###end title 53
###begin p 54
###xml 14 19 <span type="species:ncbi:9606">human</span>
The lysate of human adipose tissue was incubated with affinity-purified anti-ACC2.v2 antibody for 3 hours at 4degreesC. After adding Protein-A-agarose (Upstate, Charlottesville, VA), the incubation was continued for an additional hour. ACC protein in supernatant was precipitated by 35% saturated ammonium sulfate. The immunoprecipitate and precipitated supernatant were subject to Western blot analysis. Recombinant ACC2.v2 protein was added to the immunoprecipitation reaction as a marker of migration distance. The recombinant ACC2.v2 protein was expressed in FM3A cells and purified with HiTrap chelating column (GE Healthcare Piscataway, NJ).
###end p 54
###begin title 55
ACC enzyme assay
###end title 55
###begin p 56
###xml 42 44 42 44 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
###xml 46 47 46 47 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 100 102 100 102 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
###xml 122 124 122 124 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
###xml 308 309 302 303 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 363 364 357 358 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 379 381 373 375 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
###xml 388 389 382 383 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 547 549 533 535 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
###xml 556 557 542 543 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 753 754 739 740 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 848 849 822 823 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sub>
ACC activity was measured with a standard 14CO2 fixation assay which measures the incorporation of [14C]bicarbonate into [14C]malonyl-CoA with a 96-well plate format. Recombinant protein was incubated at 37degreesC for 40 minutes in a reaction mixture consisting of 50 mM HEPES (pH 7.5), 2 mM DTT, 20 mM MgCl2, 20 mM citrate, 4 mM acetyl-CoA, 5 mM ATP, 4 mM NaHCO3, and 0.08 mM [14C]NaHCO3 (50-62 mCi/mmol, GE Healthcare) at 80 microl/well, and the reaction was terminated by the addition of 20 microl 1 N HC1. Following evaporation of unreacted [14C]NaHCO3, radioactivity in the residue was measured with TopCount Microplate scintillation counter (PerkinElmer Inc., Wellesley, MA). For kinetic studies, the reaction was run at acetyl-CoA, ATP and NaHCO3 ranging from 3.9 to 2,000 microM, 8.7 to 5,000 microM and 80 to 8,080 microM, respectively. Km values were determined by non-linear regression analysis of initial velocities, according to the standard Michaelis-Menten equation.
###end p 56
###begin title 57
Preparation of purified recombinant proteins
###end title 57
###begin p 58
###xml 167 168 161 162 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 401 402 387 388 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 509 510 495 496 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 739 740 725 726 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 84 90 <span type="species:ncbi:9913">bovine</span>
###xml 285 291 <span type="species:ncbi:9913">bovine</span>
The FM3A cells expressing ACC2.v1 and ACC2.v2 were cultured in RPMI 1640, 10% fetal bovine serum, penicillin/streptomycin, and 0.5 mg/ml G418 at 37degrees C. and 5% CO2. The Sf9 cells were grown in Grace's Insect Cell Culture Medium (Invitrogen, Carlsbad, Calif.) containing 10% fetal bovine serum, 0.1 mg/ml kanamycin, and 0.1% PLURONIC(R) F-68 (Invitrogen, Carlsbad, Calif.) at 30degrees C and 5% CO2. Sf9 cells were collected by centrifugation and resuspended in the culture media at a cell density of 1x107 cells/ml. The Sf9 cells were then incubated with the ACC1 expression virus stock solution (moi = approximately 5) for 1 hour at room temperature. The infected Sf9 cells were diluted with the culture media to cell density of 1x106 cells, and then cultured for 3 days. The recombinant ACC proteins were purified with HiTrap chelating column (GE Healthcare Piscataway, NJ).
###end p 58
###begin title 59
De novo lipogenesis (DNL)
###end title 59
###begin p 60
###xml 74 76 74 76 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
###xml 285 286 281 282 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 566 568 544 546 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
###xml 897 899 871 873 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#8722;</sup>
DNL activity in FM3A cells was determined by whole-cell incorporation of [14C]acetate into the lipids. FM3A cells were suspended in culture medium (RPMI1640+10% FBS containing 5 mM MEM sodium pyruvate and 1 microM Simvastatin, a HMG-CoA reductase inhibitor) in at the density of 0.1x106 cell/50 microl and incubated at 37degreesC for 1 hour. After the incubation, 50 microl of culture medium were added to the cells and incubated another 1 hour in the presence or absence of 10 microM of a specific dual ACC1 and ACC2 inhibitor, labeled "compound A". 18.5 kBq of [2-14C]acetate (2.07 GBq/mmol; GE Healthcare UK Ltd.) in 10 microl of culture medium was then added to the cells and the cells were incubated for additional 1 hour. At the end of the incubation, cells were harvested onto 96 well Unifilter GF/C (PerkinElmer, Inc.) using Unifilter 96 Harvester and washed with 4 times with ice-cold PBS2-. After dry up of the plate, 30 microl/well of MicroScint 0 scintillant (PerkinElmer, Inc.) were added to the plate and then radioactivity in the insoluble lipid fraction were counted by TopCount Microplate scintillation counter (PerkinElmer, Inc.).
###end p 60
###begin title 61
Supporting Information
###end title 61
###begin p 62
###xml 37 41 37 41 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004369-Zhang2">[37]</xref>
Domains in the ACC protein structure [37], including the novel ACC2 isoform characterized here.
###end p 62
###begin p 63
(0.03 MB PPT)
###end p 63
###begin p 64
Click here for additional data file.
###end p 64
###begin p 65
###xml 17 20 <span type="species:ncbi:10116">rat</span>
###xml 25 30 <span type="species:ncbi:9606">human</span>
Alignment of the rat and human genomes at the novel exon and the start of the second exon (italics). There are no inserts or deletions after the 'ATG' start codon (purple) but many before this start site, suggesting that the protein (underlined) does not extend in the upstream direction of this ATG.
###end p 65
###begin p 66
(0.02 MB PPT)
###end p 66
###begin p 67
Click here for additional data file.
###end p 67
###begin p 68
###xml 219 226 219 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0004369.s004">Table 1</xref>
###xml 43 48 <span type="species:ncbi:9606">human</span>
###xml 107 112 <span type="species:ncbi:9606">human</span>
Detection of endogenous ACC2.v2 protein in human adipose samples. Supernatant and immunoprecipitate from a human adipose lysate was probed with streptavidin (anti-biotin) and with an anti-ACC2.v2 antibody (Supplemental Table 1) (columns A and B). The supernatant probed with streptavidin shows a band at the expected ACC2.v1 location and at the ACC1/ACC2.v2 location (column A, upper). The immunoprecipitate probed with the ACC2.v2-specific antibody (column B, lower) shows a band at the predicted ACC.v2 location, suggestive of endogenous ACC2.v2 protein expression. Columns C and D repeat the experiment after adding recombinant ACC2.v2 protein. The band location in the lower C and D panels marks the ACC2.v2 migration distance. Arrows indicate the predicted ACC2.v1, ACC1, and ACC2.v2 locations (top to bottom, respectively).
###end p 68
###begin p 69
(0.23 MB PPT)
###end p 69
###begin p 70
Click here for additional data file.
###end p 70
###begin p 71
TaqMan probe sequences
###end p 71
###begin p 72
(0.04 MB DOC)
###end p 72
###begin p 73
Click here for additional data file.
###end p 73
###begin p 74
Antibodies used
###end p 74
###begin p 75
(0.03 MB DOC)
###end p 75
###begin p 76
Click here for additional data file.
###end p 76
###begin p 77
###xml 215 218 <span type="species:ncbi:9615">dog</span>
We thank David Haynor and Eric Bachman for manuscript review and helpful suggestions, Rosetta's Gene Expression Laboratory microarray hybridization facility for microarray data, Chris Roberts and Steve Milligan for dog and rhesus microarray data, and Sherri Bloomer for project management support.
###end p 77
###begin title 78
References
###end title 78
###begin article-title 79
Evidence for the participation of biotin in the enzymic synthesis of fatty acids.
###end article-title 79
###begin article-title 80
What if Minkowski had been ageusic? An alternative angle on diabetes.
###end article-title 80
###begin article-title 81
###xml 103 107 <span type="species:ncbi:10116">rats</span>
Altered sensitivity of carnitine palmitoyltransferase to inhibition by malonyl-CoA in ketotic diabetic rats.
###end article-title 81
###begin article-title 82
A possible role for malonyl-CoA in the regulation of hepatic fatty acid oxidation and ketogenesis.
###end article-title 82
###begin article-title 83
Structure and regulation of acetyl-CoA carboxylase genes of metazoa.
###end article-title 83
###begin article-title 84
###xml 7 11 <span type="species:ncbi:10090">mice</span>
Mutant mice lacking acetyl-CoA carboxylase 1 are embryonically lethal.
###end article-title 84
###begin article-title 85
###xml 72 76 <span type="species:ncbi:10090">mice</span>
Hepatic de novo lipogenesis is present in liver-specific ACC1-deficient mice.
###end article-title 85
###begin article-title 86
###xml 59 63 <span type="species:ncbi:10090">mice</span>
Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2.
###end article-title 86
###begin article-title 87
###xml 82 86 <span type="species:ncbi:10090">mice</span>
Glucose and fat metabolism in adipose tissue of acetyl-CoA carboxylase 2 knockout mice.
###end article-title 87
###begin article-title 88
###xml 32 36 <span type="species:ncbi:10090">mice</span>
Acetyl-CoA carboxylase 2 mutant mice are protected against obesity and diabetes induced by high-fat/high-carbohydrate diets.
###end article-title 88
###begin article-title 89
Isozyme-nonselective N-substituted bipiperidylcarboxamide acetyl-CoA carboxylase inhibitors reduce tissue malonyl-CoA concentrations, inhibit fatty acid synthesis, and increase fatty acid oxidation in cultured cells and in experimental animals.
###end article-title 89
###begin article-title 90
Acetyl-CoA carboxylase inhibition for the treatment of metabolic syndrome.
###end article-title 90
###begin article-title 91
Lipid metabolic enzymes: emerging drug targets for the treatment of obesity.
###end article-title 91
###begin article-title 92
Identification of an isozymic form of acetyl-CoA carboxylase.
###end article-title 92
###begin article-title 93
###xml 11 16 <span type="species:ncbi:9606">human</span>
Cloning of human acetyl-CoA carboxylase-beta and its unique features.
###end article-title 93
###begin article-title 94
Acetyl-CoA carboxylase regulation of fatty acid oxidation in the heart.
###end article-title 94
###begin article-title 95
The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis.
###end article-title 95
###begin article-title 96
The subcellular localization of acetyl-CoA carboxylase 2.
###end article-title 96
###begin article-title 97
###xml 78 83 <span type="species:ncbi:9606">human</span>
Cloning, expression, characterization, and interaction of two components of a human mitochondrial fatty acid synthase. Malonyltransferase and acyl carrier protein.
###end article-title 97
###begin article-title 98
Regulation of fatty acid synthesis and oxidation by the AMP-activated protein kinase.
###end article-title 98
###begin article-title 99
###xml 62 67 <span type="species:ncbi:9606">human</span>
Exercise diminishes the activity of acetyl-CoA carboxylase in human muscle.
###end article-title 99
###begin article-title 100
Malonyl-CoA, fuel sensing, and insulin resistance.
###end article-title 100
###begin article-title 101
###xml 98 101 <span type="species:ncbi:10116">rat</span>
Unique structural features and differential phosphorylation of the 280-kDa component (isozyme) of rat liver acetyl-CoA carboxylase.
###end article-title 101
###begin article-title 102
Optimization of oligonucleotide arrays and RNA amplification protocols for analysis of transcript structure and alternative splicing.
###end article-title 102
###begin article-title 103
###xml 27 32 <span type="species:ncbi:9606">human</span>
Identification of a second human acetyl-CoA carboxylase gene.
###end article-title 103
###begin article-title 104
Regulation of acetyl-coenzyme A carboxylase. II. Effect of fasting and refeeding on the activity, phosphate content, and aggregation state of the enzyme.
###end article-title 104
###begin article-title 105
Contraction-induced changes in acetyl-CoA carboxylase and 5'-AMP-activated kinase in skeletal muscle.
###end article-title 105
###begin article-title 106
###xml 66 72 <span type="species:ncbi:9606">humans</span>
Effect of exercise intensity on skeletal muscle AMPK signaling in humans.
###end article-title 106
###begin article-title 107
###xml 22 27 <span type="species:ncbi:9606">human</span>
Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays.
###end article-title 107
###begin article-title 108
Expression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer.
###end article-title 108
###begin article-title 109
A computer program for aligning a cDNA sequence with a genomic DNA sequence.
###end article-title 109
###begin article-title 110
EST_GENOME: a program to align spliced DNA sequences to unspliced genomic DNA.
###end article-title 110
###begin article-title 111
###xml 65 70 <span type="species:ncbi:9606">human</span>
Computational identification of promoters and first exons in the human genome.
###end article-title 111
###begin article-title 112
Phylogenetic estimation of context-dependent substitution rates by maximum likelihood.
###end article-title 112
###begin article-title 113
The UCSC Genome Browser Database.
###end article-title 113
###begin article-title 114
Crystal structure of the carboxyltransferase domain of acetyl-coenzyme A carboxylase.
###end article-title 114
###begin p 115
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 115
###begin p 116
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: All authors worked for Merck & Co or a subsidiary. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 116

